Published on Jun 16, 2011 by Edgar Snyder

FDA Warns Healthcare Providers of Victoza’s Effects

syringe of Victoza drug

The Food and Drug Administration (FDA) sent a letter to healthcare professionals after a recent assessment showed many healthcare providers are not aware of Victoza's (liraglutide) serious risks.

Liraglutide was approved by the FDA in January 2010 to treat type 2 diabetes (non-insulin dependent). It is available in a pre-filled injection pen and is injected under the skin. The drug controls blood sugar levels by increasing the amount of insulin patients' bodies produce.

According to reports, patients taking Victoza have had more cases of pancreatitis compared to those taking comparable medications. Also, clinical studies in mice and rats have found that liraglutide causes thyroid C-cell tumors, depending on the dosage and duration of treatment. However, it has not yet been proven to have the same effects in humans.

Patients being treated with Victoza should watch for symptoms of pancreatitis like: persistent severe abdominal pain, back pain, and vomiting. For more information on dangerous drugs, visit

"Victoza Injection: REMS - Risk of Thyroid C-Cell Tumors, Acute Pancreatitis." MedWatch. June 13, 2011.
Free Case Review
First Name
Last Name
Briefly describe your injuries